984P FIPO23: A first-in-human trial of XON7, a Glyco-Humanized Polyclonal Antibody (GHpAb)targeting multiple tumor antigens in advanced solid tumors

J. Bennouna; Françoise Shneiker; Jean Yves Blay; J.P. Delord; M. Brahmi; Firas Bassissi; Raffaele Ratta; Carlos Gomez‐Roca; Philippe A. Cassier; Asmahane Benmaziane; Christiane Jungels; Iphigénie Korakis; Ahmad Awada

doi:10.1016/j.annonc.2025.08.1553

Back

Shared by

Jean Yves Blay

984P FIPO23: A first-in-human trial of XON7, a Glyco-Humanized Polyclonal Antibody (GHpAb)targeting multiple tumor antigens in advanced solid tumors

Article 2025 en

Authors

JB
J. Bennouna
FS
Françoise Shneiker
Jean Yves Blay

Related publications

Article2024

The FIPO23 trial: First-in-human phase I/II study of XON7 in advanced solids tumors.

Jaafar Bennouna, Françoise Shneiker, Jean Yves Blay, Ahmad Awada, Firas Bassissi, Raffaele Ratta, Jean‐Pierre Delord

Article2010

Pre-final analysis of first-in-human, first-in-class, phase I clinical trial of CNTO 888, a human monoclonal antibody to the CC-chemokine ligand 2 (CCL2) in patients (pts) with advanced solid tumors.

Martin Förster, Amita Patnaik, Shahneen Sandhu, K. Papadopoulos, Brenda Tromp, Christina Messiou, Frances R. Balkwill, Birge Berns, Johann S. de Bono, A. W. Tolcher

Article2025

Phase I First-in-Human Study of TRK-950, an IgG1 Antibody Specific to CAPRIN-1, in Patients with Advanced Solid Tumors

Philippe A. Cassier, Mitesh J. Borad, Sunil Sharma, Bertrand Dubois, Christophe Caux, Fumiyoshi Okano, Daniel D. Von Hoff, Jean Yves Blay

Preprint2025

Data from Phase I First-in-Human Study of TRK-950, an IgG1 Antibody Specific to CAPRIN-1, in Patients with Advanced Solid Tumors

Philippe A. Cassier, Mitesh J. Borad, Sunil Sharma, Bertrand Dubois, Christophe Caux, Fumiyoshi Okano, Daniel D. Von Hoff, Jean Yves Blay

Article2013

A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors

Shahneen Sandhu, K. Papadopoulos, Peter C.C. Fong, Amita Patnaik, Christina Messiou, David Olmos, George Wang, Brenda Tromp, Thomas A. Puchalski, Frances R. Balkwill, Birge Berns, Shobha Seetharam, Johann S. de Bono, Anthony W. Tolcher

984P FIPO23: A first-in-human trial of XON7, a Glyco-Humanized Polyclonal Antibody (GHpAb)targeting multiple tumor antigens in advanced solid tumors

Discussion(0)

Related publications

The FIPO23 trial: First-in-human phase I/II study of XON7 in advanced solids tumors.

Pre-final analysis of first-in-human, first-in-class, phase I clinical trial of CNTO 888, a human monoclonal antibody to the CC-chemokine ligand 2 (CCL2) in patients (pts) with advanced solid tumors.

Phase I First-in-Human Study of TRK-950, an IgG1 Antibody Specific to CAPRIN-1, in Patients with Advanced Solid Tumors

Data from Phase I First-in-Human Study of TRK-950, an IgG1 Antibody Specific to CAPRIN-1, in Patients with Advanced Solid Tumors

A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors